Impact of COVID-19 on Patient Demographics and Length of Stay in Florida
COVID-19 pandemic led to a shift in patient demographics, with a higher proportion of super elderly patients who experienced longer lengths of stay.
Post-pandemic, the conditions are improving, leading to a reduction in the previously elevated average length of stay, which increased from 100.6 days in 2024 to 137.1 days in 2025.
Management expects these demographic shifts to stabilize, supporting higher future growth rates.
Management reports healthy same-store sales growth in Sterigenics, with no material pull-forward effects from supply chain shifts or tariffs.
The company is actively engaging with customers on supply chain optimization but has not observed significant volume increases due to supply chain relocations.
Future opportunities for supply chain optimization are being explored, but current capacity and performance remain stable, with no adverse impact on growth.
Strong and Sustained Revenue Growth in Core Business and New Launch Countries
Amicus reported 17th consecutive quarter of double-digit revenue growth at CER, driven by Pompe and Fabry disease.
Q2 revenue reached $154.7 million, up 22% YoY, with significant contributions from newly launched countries including Italy, Switzerland, Portugal, Czech Republic, Sweden, and the Netherlands.
The company expects continued growth in these markets and plans to launch in up to 10 new countries in 2025.
Capital Allocation and Shareholder Return Strategy
The company is committed to returning capital to shareholders through share repurchases and debt reduction, leveraging improved EBITDA and free cash flow.
Management announced a plan to reduce stock-based compensation as a percentage of revenue to mid- to high-single digits in 2026.
The company has no near-term plans for acquisitions, focusing instead on profitability and organic growth.
Leadership emphasizes that profitability improvements will help close the gap between intrinsic and market value, benefiting shareholders.
Dafinchi
